Figure 1From: Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapyOverall and progression-free survivals as differentiated by SUV max . A: Overall survival differences between SUVmax categories, p= 0.024; B: Progression-free survival differences between SUVmax categories, p= 0.024.Back to article page